Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 2/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660915 | 1.00 | PRKDC (0.35) | PRKDCMAPTNPSR1MEN1ALDH1A1 | |
| SCHEMBL4759175 | 0.90 | ACACB (0.33) | — | |
| SCHEMBL3864467 | 0.83 | PIK3CA (0.33) | PIK3CA | |
| SCHEMBL4266728 | 0.81 | OPRD1 (0.32) | — | |
| SCHEMBL4267712 | 0.81 | OPRD1 (0.32) | — | |
| SCHEMBL2362040 | 0.81 | ACACB (0.35) | — | |
| SCHEMBL4412678 | 0.81 | ACACB (0.35) | — | |
| SCHEMBL4266808 | 0.81 | OPRD1 (0.32) | — | |
| SCHEMBL4760383 | 0.80 | ACACB (0.34) | — | |
| SCHEMBL502513 | 0.80 | ACACB (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218149-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
| EP-2680851-A2 | FUSED BICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012118945-A2 | FUSED BICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2010138343-A1 | NEUROMEDIN U RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218149-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | PRKAG2, AK2, PRKAB2 | PRKDC 1051/4885MAPT 2676/4885NPSR1 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.